



MATINS
HEALTHCARE PVT. LTD.

MATINS HEALTHCARE PVT. LTD.

PLOT No.-10, SECTOR-5, IIE, SIDCUL, HARIDWAR
Mfg. Licence No.: 61/UA/SC/P-2006 & 62/UA/2006

QUALITY CONTROL DEPARTMENT (FINISHED)

(The Drugs & Cosmetics Act 1940 and the Rules there under)

CERTIFICATE OF ANALYSIS

Product Name	HEALMARYL MV 2.3	A.R. No.	FGT-240223
Generic Name	Metformin HCl (SR), Glimepiride & Voglibose Tablets	Batch Size	1.0 Lac Tablets
Batch No.	MT-240091	Sample Qty.	100 Tablets
Mfg. Date	01/2024	Sample received date	27/01/2024
Exp. Date	12/2025	Date of Release	29/01/2024

Sr. No.	TESTS	SPECIFICATIONS	RESULTS
1	Description	Pink/White colour elongated, biconvex, uncoated bilayer tablets	Pink/White colour elongated, biconvex, uncoated bilayer tablets
2	Identification: By HPLC	The retention time of the major peak in the chromatogram of the sample solution corresponds to that in the chromatogram of the standard solution, as obtained in the assay.	Complies
3	Average weight	850 mg $\pm$ 5% (807.5 to 892.5 mg)	848.30 mg
4	Uniformity of weight	$\pm$ 5% on average weight	Positive deviation= 2.25% Negative deviation= 2.19%
5	Uniformity of contents		
	For Glimepiride	NLT 85% to NMT 115%	95.85% to 101.49%
	For Voglibose	NLT 85% to NMT 115%	96.23% to 103.22%
6	Dissolution		
	For Metformin Hydrochloride		
	After 1 st hour	NMT 40%	24.13% to 30.56%
	After 3 rd hour	45% to 75%	57.27% to 63.18%
7	Assay: Each uncoated bilayer tablet contains:		
	Metformin Hydrochloride IP 500 mg (As Sustained release)	Not Less Than 90% and Not More Than 110% (450.0 mg to 550.0 mg)	508.05 mg (101.60%)
	Glimepiride IP 2 mg	Not Less Than 90% and Not More Than 110% (1.8 mg to 2.2 mg)	1.97 mg (98.50%)
	Voglibose IP 0.3 mg	Not Less Than 90% and Not More Than 110% (0.27 mg to 0.33 mg)	0.301 mg (100.33%)

Remarks: The product complies as per IHS Specification.

Cy
29/01/2024
Analyzed by

M
29/01/2024
Checked by

[Signature]
29/01/2024
Approved by